GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
NEW YORK, March 03, 2016 -- Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of HeartWare International Inc. securities (NASDAQ:HTWR) from June 10, 2014 through January 11, 2016, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for HeartWare investors under the federal securities laws.
To join the HeartWare class action, go to the firm’s website at http://www.rosenlegal.com/cases-750.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants falsely assured investors that HeartWare had adequately addressed numerous manufacturing and other regulatory failures at HeartWare’s sole manufacturing facility, and that the failures, which had been identified by the U.S. Food and Drug Administration (FDA) in a Warning Letter, posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is presently developing. When the true details concerning HeartWare’s failure to remediate the regulatory problems identified by the FDA and its impact on MVAD entered the market, HeartWare’s share price declined, causing investors damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-750.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
